Changing the Statistic in Women’s Heart Health
The Statistic
100% of women experience menopause.
Yet only about 5–10% of eligible women receive menopausal hormone therapy.
At the same time, cardiovascular disease remains the leading cause of death in women in the United States.
-
About 1 in 3 female deaths are due to cardiovascular disease.
-
Nearly 45% of women over age 20 have some form of cardiovascular disease.
Source: American Heart Association Heart Disease & Stroke Statistics Update (2024)
For decades, many women and clinicians avoided hormone therapy after the 2002 Women’s Health Initiative (WHI) study raised concerns about breast cancer and cardiovascular risk.
But the story did not end there.
The Women’s Health Initiative (WHI): A Lesson in Scientific Interpretation
In 2002, results from the Women’s Health Initiative trial were widely interpreted to mean that hormone therapy increased the risk of breast cancer and heart disease.
The study led to a dramatic drop in hormone therapy use worldwide.
However, later analysis revealed important context.
The average participant in the WHI trial
-
Was 63 years old (older than most people start therapy in real clinical practice)
-
Often more than 10 years past menopause (missed window of opportunity for cardiovascular protection)
Subsequent re-analysis of the data found that:
-
Age and timing of therapy matter
-
Starting hormone therapy closer to menopause may have different cardiovascular effects than starting many years later
This concept is now known as the “timing hypothesis.”
Sources:
Manson et al., New England Journal of Medicine follow-up analyses
The Menopause Society Position Statement (2022)
Hormone Transitions and Cardiovascular Risk
Menopause is associated with physiologic changes that influence cardiovascular risk.
These include:
-
Changes in lipid metabolism
-
Increased visceral fat accumulation
-
Increased insulin resistance
-
Changes in vascular function
Research has also shown that vasomotor symptoms (hot flashes) may correlate with markers of vascular dysfunction.
Sources:
Thurston et al., Circulation
The Menopause Society
Metabolic Health and Cardiovascular Risk
Metabolic dysfunction is a major driver of cardiovascular disease.
Key contributors include:
-
Visceral fat accumulation
-
Insulin resistance
-
Chronic inflammation
GLP-1 receptor agonist medications have been shown to:
-
Improve blood sugar regulation
-
Reduce visceral adiposity
-
Lower cardiovascular event risk in certain populations
Sources:
LEADER Trial
SUSTAIN-6 Trial
SELECT Trial (Semaglutide Cardiovascular Outcomes)
Hormones and Bone Health
Estrogen plays a key role in maintaining bone density.
Loss of estrogen after menopause can accelerate bone loss and increase risk of osteoporosis and fractures.
Hip fractures in older adults are associated with significant mortality risk.
Preventing bone loss is an important component of long-term women’s health.
Source:
The Menopause Society
Heart Disease vs Breast Cancer
Breast cancer receives significant public awareness.
However, heart disease kills far more women each year than breast cancer.
Both matter, but understanding the true drivers of mortality helps guide prevention.
Sources:
American Heart Association
CDC
Hormones in Women
Women naturally produce multiple hormones that influence whole-body health, including:
• Estrogen
• Progesterone
• Testosterone
These hormones affect cardiovascular health, bone density, metabolism, brain function, and energy levels.
Prevention Starts With Listening
Many women report symptoms that are dismissed as “normal aging.”
But early physiologic signals can provide an opportunity for prevention.
Recognizing patterns, asking questions, and interpreting research critically helps improve outcomes.
Change the Statistic
When we learn to question assumptions, interpret research carefully, and recognize patterns others overlook,
we don’t just treat disease.
We change the statistic.